Browsing Tag
IBTROZI
2 posts
Nuvation Bio adds FDA Fast Track to safusidenib as Phase 3 enrollment builds
Nuvation Bio has secured FDA Fast Track designation for safusidenib in IDH1-mutant glioma, adding regulatory momentum to a program backed by long-term Phase 2 responses and an expanding Phase 3 strategy.
Why updated TRUST-I and TRUST-II results make IBTROZI a top contender in targeted lung cancer therapy
Nuvation Bio unveils pivotal TRUST-I and TRUST-II updates for IBTROZI in ROS1+ lung cancer, showing strong durability and brain response. Read more now.